These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 9176967)

  • 1. The relationship between parameters of serotonin metabolism and emetogenic potential of platinum-based chemotherapy regimens.
    du Bois A; Vach W; Siebert C; Holy R; Ledergerber M; Wechsel U; Kriesinger-Schroeder H
    Support Care Cancer; 1997 May; 5(3):212-8. PubMed ID: 9176967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in serotonin metabolism in cancer patients: its relationship to nausea and vomiting induced by chemotherapeutic drugs.
    Cubeddu LX; Hoffmann IS; Fuenmayor NT; Malave JJ
    Br J Cancer; 1992 Jul; 66(1):198-203. PubMed ID: 1379060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the emetogenic potential between cisplatin and carboplatin in combination with alkylating agents.
    du Bois A; Vach W; Thomssen C; Karck U; Madjar H; Prömpeler H; Meerpohl HG
    Acta Oncol; 1994; 33(5):531-5. PubMed ID: 7917367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urinary 5-hydroxyindoleacetic acid (5-HIAA) excretion during multiple-day high-dose chemotherapy.
    Janes RJ; Muhonen T; Karjalainen UP; Wiklund T
    Eur J Cancer; 1998 Jan; 34(1):196-8. PubMed ID: 9624258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of intravenous microdialysis to monitor changes in serotonin release and metabolism induced by cisplatin in cancer patients: comparative effects of granisetron and ondansetron.
    Castejon AM; Paez X; Hernandez L; Cubeddu LX
    J Pharmacol Exp Ther; 1999 Dec; 291(3):960-6. PubMed ID: 10565811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Oral NEPA (Netupitant/Palonosetron), the First Fixed-Combination Antiemetic, in Patients With Gynecological Cancers Receiving Platinum-Based Chemotherapy.
    Bošnjak SM; Stamatovic L; Borroni ME; Rizzi G; Jordan K
    Int J Gynecol Cancer; 2018 Jul; 28(6):1153-1161. PubMed ID: 29794499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of serotonin as a mediator of emesis induced by different stimuli.
    du Bois A; Kriesinger-Schroeder H; Meerpohl HG
    Support Care Cancer; 1995 Sep; 3(5):285-90. PubMed ID: 8520873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 5-Hydroxyindoleacetic acid excretion following combination chemotherapy with cyclophosphamide, epirubicin and 5-fluorouracil plus ondansetron compared to ondansetron alone.
    du Bois A; Vach W; Holy R; Kriesinger-Schröder H
    Support Care Cancer; 1996 Sep; 4(5):384-9. PubMed ID: 8883233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 5-Hydroxyindoleacetic acid (5-HIAA) and cortisol excretion as predictors of chemotherapy-induced emesis.
    du Bois A; Vach W; Wechsel U; Holy R; Schaefer W
    Br J Cancer; 1996 Oct; 74(7):1137-40. PubMed ID: 8855988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative toxicity of cisplatin, carboplatin (CBDCA) and iproplatin (CHIP) in combination with cyclophosphamide in patients with advanced epithelial ovarian cancer.
    Anderson H; Wagstaff J; Crowther D; Swindell R; Lind MJ; McGregor J; Timms MS; Brown D; Palmer P
    Eur J Cancer Clin Oncol; 1988 Sep; 24(9):1471-9. PubMed ID: 3053207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative study of the acute nephrotoxicity from standard dose cisplatin +/- ifosfamide and high-dose chemotherapy with carboplatin and ifosfamide.
    Hartmann JT; Fels LM; Franzke A; Knop S; Renn M; Maess B; Panagiotou P; Lampe H; Kanz L; Stolte H; Bokemeyer C
    Anticancer Res; 2000; 20(5C):3767-73. PubMed ID: 11268452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date.
    Harper P
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Participation of serotonin on early and delayed emesis induced by initial and subsequent cycles of cisplatinum-based chemotherapy: effects of antiemetics.
    Cubeddu LX; Hoffmann IS
    J Clin Pharmacol; 1993 Aug; 33(8):691-7. PubMed ID: 7691898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with para-chlorophenylalanine antagonises the emetic response and the serotonin-releasing actions of cisplatin in cancer patients.
    Alfieri AB; Cubeddu LX
    Br J Cancer; 1995 Mar; 71(3):629-32. PubMed ID: 7533519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emesis induced in domestic pigs: a new experimental tool for detection of antiemetic drugs and for evaluation of emetogenic potential of new anticancer agents.
    Szelenyi I; Herold H; Göthert M
    J Pharmacol Toxicol Methods; 1994 Oct; 32(2):109-16. PubMed ID: 7865862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacokinetic investigation of 5-day multiple dose of tropisetron capsule in patients who had received cisplatin and the usefulness of tropisetron capsule in the treatment of nausea and vomiting].
    Suminaga M; Akasaka Y; Nukariya N; Kimura A; Ohtawa M
    Gan To Kagaku Ryoho; 1995 Aug; 22(9):1209-21. PubMed ID: 7544965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma chromogranin A marks emesis and serotonin release associated with dacarbazine and nitrogen mustard but not with cyclophosphamide-based chemotherapies.
    Cubeddu LX; O'Connor DT; Hoffmann I; Parmer RJ
    Br J Cancer; 1995 Oct; 72(4):1033-8. PubMed ID: 7547218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cisplatin-induced alterations of serotonin metabolism in patients with or without emesis following chemotherapy.
    Dubois A; Siebert C; Vach W; Kriesingerschroeder H
    Oncol Rep; 1995 Sep; 2(5):839-42. PubMed ID: 21597827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination chemotherapy with cisplatin, carboplatin, and etoposide in advanced malignancy: a phase I trial.
    Rajkumar SV; Frytak S; Rubin J; Camoriano JK; Fitch TR
    Am J Clin Oncol; 1997 Oct; 20(5):500-4. PubMed ID: 9345336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclophosphamide-cisplatin versus cyclophosphamide-carboplatin in stage III-IV ovarian carcinoma: a comparison of equally myelosuppressive regimens.
    Edmonson JH; McCormack GM; Wieand HS; Kugler JW; Krook JE; Stanhope CR; Everson LK; Laurie JA; Ebbert LP; Malkasian GD
    J Natl Cancer Inst; 1989 Oct; 81(19):1500-4. PubMed ID: 2674460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.